|
1
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar
|
|
2
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar
|
|
5
|
Shen YW, Zhang XM, Li ST, Lv M and Yang J,
Wang F, Chen ZL, Wang BY, Li P, Chen L and Yang J: Efficacy and
safety of icotinib as first-line therapy in patients with advanced
non-small-cell lung cancer. Onco Targets Ther. 9:929–935. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu YL, Zhou C, Cheng Y, Lu S, Chen GY,
Huang C, Huang YS, Yan HH, Ren S, Liu Y and Yang JJ: Erlotinib as
second-line treatment in patients with advanced non-small-cell lung
cancer and asymptomatic brain metastases: A phase II study
(CTONG-0803). Ann Oncol. 24:993–999. 2013. View Article : Google Scholar
|
|
7
|
Iuchi T, Shingyoji M, Sakaida T, Hatano K,
Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K
and Iizasa T: Phase II trial of gefitinib alone without radiation
therapy for Japanese patients with brain metastases from
EGFR-mutant lung adenocarcinoma. Lung Cancer. 82:282–287. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roper N, Brown AL, Wei JS, Pack S,
Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, et al:
Clonal evolution and heterogeneity of osimertinib acquired
resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med.
1:1000072020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong
V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, et al:
First-line erlotinib therapy until and beyond response evaluation
criteria in solid tumors progression in asian patients with
epidermal growth factor receptor Mutation-positive Non-Small-Cell
lung cancer: The ASPIRATION study. JAMA Oncol. 2:305–312. 2016.
View Article : Google Scholar
|
|
10
|
Chaft JE, Oxnard GR, Sima CS, Kris MG,
Miller VA and Riely GJ: Disease flare after tyrosine kinase
inhibitor discontinuation in patients with EGFR-mutant lung cancer
and acquired resistance to erlotinib or gefitinib: Implications for
clinical trial design. Clin Cancer Res. 17:6298–6303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heitmann J and Guckenberger M:
Perspectives on oligometastasis: Challenges and opportunities. J
Thorac Dis. 10:113–117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, Hu
P, Wang H, Zhang Y, Shen Y, et al: Efficacy of local consolidative
therapy for oligometastatic lung adenocarcinoma patients harboring
epidermal growth factor receptor mutations. Clin Lung Cancer.
20:e81–e90. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seong H, Kim SH, Kim MH, Kim J and Eom JS:
Additional local therapy before disease progression for
EGFR-mutated advanced lung cancer: A systematic review and
meta-analysis. Transl Lung Cancer Res. 13:491–502. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y,
Li P and Chang JY: Promising clinical outcome of stereotactic body
radiation therapy for patients with inoperable Stage I/II
non-small-cell lung cancer. Int J Radiat Oncol Biol Phys.
66:117–125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang LP, Nie Q, Kang JB, Wang B, Cai CL,
Li JG and Qi WJ: Efficacy of whole body gamma-knife radiotherapy
combined with thermochemotherapy on locally advanced pancreatic
cancer. Chin J Cancer. 27:1204–1207. 2008.(In Chinese).
|
|
16
|
Yu W, Tang L, Lin F, Li D, Wang J, Yang Y
and Shen Z: Stereotactic radiosurgery, a potential alternative
treatment for pulmonary metastases from osteosarcoma. Int J Oncol.
44:1091–1098. 2014. View Article : Google Scholar
|
|
17
|
Liu K, Zheng D, Xu G, Du Z and Wu S: Local
thoracic therapy improve prognosis for stage IV non-small cell lung
cancer patients combined with chemotherapy: A Surveillance,
Epidemiology, and End Results database analysis. PLoS One.
12:e01873502017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gomez DR, Tang C, Zhang J, Blumenschein GR
Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et
al: Local consolidative therapy vs. maintenance therapy or
observation for patients with oligometastatic Non-Small-Cell lung
cancer: Long-Term results of a Multi-Institutional, Phase II,
randomized study. J Clin Oncol. 37:1558–1565. 2019. View Article : Google Scholar
|
|
19
|
Palma DA, Olson R, Harrow S, Gaede S,
Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP,
et al: Stereotactic ablative radiotherapy for the comprehensive
treatment of oligometastatic cancers: Long-term results of the
SABR-COMET phase II randomized trial. J Clin Oncol. 38:2830–2838.
2020. View Article : Google Scholar
|
|
20
|
Wang XS, Bai YF, Verma V, Yu RL, Tian W,
Ao R, Deng Y, Zhu XQ, Liu H, Pan HX, et al: Randomized trial of
First-line tyrosine kinase inhibitor with or without radiotherapy
for synchronous oligometastatic EGFR-Mutated Non-Small cell lung
cancer. J Natl Cancer Inst. 115:742–748. 2023. View Article : Google Scholar
|
|
21
|
Kuo SW, Chen PH, Lu TP, Chen KC, Liao HC,
Tsou KC, Tsai TM, Lin MW, Hsu HH and Chen JS: Primary tumor
resection for Stage IV Non-small-cell lung cancer without
progression After First-Line epidermal growth factor
receptor-tyrosine kinase inhibitor treatment: A retrospective
Case-Control study. Ann Surg Oncol. 29:4873–4884. 2022. View Article : Google Scholar
|
|
22
|
Hsu KH, Huang JW, Tseng JS, Chen KW, Weng
YC, Yu SL, Yang TY, Huang YH, Chen JJW, Chen KC, et al: Primary
tumor radiotherapy during EGFR-TKI disease control improves
survival of treatment naïve advanced EGFR-Mutant lung
adenocarcinoma patients. Onco Targets Ther. 14:2139–2148. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han
G, Meng R, Chen Y, Yang M, Shen Q, et al: EGFR-TKIs plus
stereotactic body radiation therapy (SBRT) for stage IV Non-small
cell lung cancer (NSCLC): A prospective, multicenter, randomized,
controlled phase II study. Radiother Oncol. 184:1096812023.
View Article : Google Scholar
|
|
24
|
Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y
and Zhou C: Consolidative local ablative therapy improves the
survival of patients with synchronous oligometastatic NSCLC
harboring EGFR Activating mutation treated with first-line
EGFR-TKIs. J Thorac Oncol. 13:1383–1392. 2018. View Article : Google Scholar
|
|
25
|
Wang Y, Li Y, Xia L, Niu K, Chen X, Lu D,
Kong R, Chen Z and Sun J: Continued EGFR-TKI with concurrent
radiotherapy to improve time to progression (TTP) in patients with
locally progressive non-small cell lung cancer (NSCLC) after
front-line EGFR-TKI treatment. Clin Transl Oncol. 20:366–373. 2018.
View Article : Google Scholar
|
|
26
|
Chiou GY, Chiang CL, Yang HC, Shen CI, Wu
HM, Chen YW, Chen CJ, Luo YH, Hu YS, Lin CJ, et al: Combined
stereotactic radiosurgery and tyrosine kinase inhibitor therapy
versus tyrosine kinase inhibitor therapy alone for the treatment of
non-small cell lung cancer patients with brain metastases. J
Neurosurg. 137:563–570. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu JJ, Tseng JS, Zheng ZR, Chu CH, Chen
KC, Lin MW, Huang YH, Hsu KH, Yang TY, Yu SL, et al: Primary tumor
consolidative therapy improves the outcomes of patients with
advanced EGFR-mutant lung adenocarcinoma treated with first-line
osimertinib. Ther Adv Med Oncol. 16:175883592312206062024.
View Article : Google Scholar
|
|
28
|
Guo T, Ni J, Yang X, Li Y, Li Y, Zou L,
Wang S, Liu Q, Chu L, Chu X, et al: Pattern of Recurrence analysis
in metastatic EGFR-Mutant NSCLC treated with osimertinib:
Implications for consolidative stereotactic body radiation therapy.
Int J Radiat Oncol Biol Phys. 107:62–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ando M, Ando Y, Hasegawa Y, Shimokata K,
Minami H, Wakai K, Ohno Y and Sakai S: Prognostic value of
performance status assessed by patients themselves, nurses, and
oncologists in advanced non-small cell lung cancer. Br J Cancer.
85:1634–1639. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: NCCN guidelines insights: Non-Small cell lung cancer,
version 2022. J Natl Compr Canc Netw. 20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar
|
|
33
|
Ju X, Li M, Zhou Z, Zhang K, Han W, Fu G,
Cao Y and Wang L: 4D-CT-based plan target volume (PTV) definition
compared with conventional PTV definition using general margin in
radiotherapy for lung cancer. Zhonghua Zhong Liu Za Zhi. 36:34–38.
2014.(In Chinese).
|
|
34
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the radiation therapy oncology group (RTOG) and the
european organization for research and treatment of cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang S, Sun Q, Cai F, Li H and Zhou Y:
Local therapy treatment conditions for oligometastatic non-small
cell lung cancer. Front Oncol. 12:10281322022. View Article : Google Scholar
|
|
36
|
Iyengar P, Wardak Z, Gerber DE, Tumati V,
Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, et
al: Consolidative radiotherapy for limited metastatic
Non-Small-Cell lung cancer: A Phase 2 randomized clinical trial.
JAMA Oncol. 4:e1735012018. View Article : Google Scholar
|
|
37
|
Ohtaki Y, Shimizu K, Suzuki H, Suzuki K,
Tsuboi M, Mitsudomi T, Takao M, Murakawa T, Ito H, Yoshimura K, et
al: Salvage surgery for non-small cell lung cancer after tyrosine
kinase inhibitor treatment. Lung Cancer. 153:108–116. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tseng JS, Hsu KH, Zheng ZR, Yang TY, Chen
KC, Huang YH, Su KY, Yu SL and Chang GC: Primary tumor resection is
associated with a better outcome among advanced EGFR-Mutant lung
adenocarcinoma patients receiving EGFR-TKI treatment. Oncology.
99:32–40. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takenaka M, Tanaka F, Kajiyama K, Manabe
T, Yoshimatsu K, Mori M, Kanayama M, Taira A, Kuwata T, Nawata A
and Kuroda K: Outcomes and pathologic response of primary lung
cancer treated with tyrosine kinase inhibitor/immune checkpoint
inhibitor before salvage surgery. Surg Today. 54:1146–1153. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Elamin YY, Gomez DR, Antonoff MB,
Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X,
Rinsurogkawong W, et al: Local consolidation therapy (LCT) after
first line tyrosine kinase inhibitor (TKI) for patients with EGFR
mutant metastatic Non-small-cell lung cancer (NSCLC). Clin Lung
Cancer. 20:43–47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng R, Liu J, Song T, Xu T, Li Y, Duo L,
Xiang L, Yu X, Lei J and Cao F: Primary lesion radiotherapy during
first-line icotinib treatment in EGFR-mutated NSCLC patients with
multiple metastases and no brain metastases: A single-center
retrospective study. Strahlenther Onkol. 198:1082–1093. 2022.
View Article : Google Scholar
|
|
42
|
Chang SJ and Bristow RE: Evolution of
surgical treatment paradigms for advanced-stage ovarian cancer:
Redefining ‘optimal’ residual disease. Gynecol Oncol. 125:483–492.
2012. View Article : Google Scholar
|
|
43
|
Koole S, van Stein R, Sikorska K, Barton
D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A and
Colombo PE: Primary cytoreductive surgery with or without
hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage
III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized
clinical trial. Int J Gynecol Cancer. 30:888–892. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin MW, Yu SL, Hsu YC, Chen YM, Lee YH,
Hsiao YJ, Lin JW, Su TJ, Jeffrey Yang CF, Chiang XH, et al: Salvage
surgery for advanced lung adenocarcinoma after epidermal growth
factor receptor tyrosine kinase inhibitor treatment. Ann Thorac
Surg. 116:111–119. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Al-Halabi H, Sayegh K, Digamurthy SR,
Niemierko A, Piotrowska Z, Willers H and Sequist LV: Pattern of
failure analysis in metastatic EGFR-Mutant lung cancer treated with
tyrosine kinase inhibitors to identify candidates for consolidation
stereotactic body radiation therapy. J Thorac Oncol. 10:1601–1607.
2015. View Article : Google Scholar
|
|
46
|
Wee P and Wang Z: Epidermal growth factor
receptor cell proliferation signaling pathways. Cancers (Basel).
9:522017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Byrne NM, Tambe P and Coulter JA:
Radiation response in the tumour microenvironment: Predictive
biomarkers and future perspectives. J Pers Med. 11:532021.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Won YW, Han JY, Lee GK, Park SY, Lim KY,
Yoon KA, Yun T, Kim HT and Lee JS: Comparison of clinical outcome
of patients with non-small-cell lung cancer harbouring epidermal
growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol.
64:947–952. 2011. View Article : Google Scholar
|
|
49
|
Hong W, Wu Q, Zhang J and Zhou Y:
Prognostic value of EGFR 19-del and 21-L858R mutations in patients
with non-small cell lung cancer. Oncol Lett. 18:3887–3895.
2019.
|
|
50
|
Chen Y, Wang S, Zhang B, Zhao Y, Zhang L,
Hu M, Zhang W and Han B: Clinical factors affecting the response to
osimertinib in Non-Small cell lung cancer patients with an acquired
epidermal growth factor receptor T790M mutation: A Long-Term
survival analysis. Target Oncol. 15:337–345. 2020. View Article : Google Scholar
|
|
51
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-Mutated
advanced Non-Small-Cell Lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall survival with osimertinib in
untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50.
2020. View Article : Google Scholar : PubMed/NCBI
|
